Literature DB >> 2828115

The 5'-CA DNA-sequence preference of daunomycin.

A Skorobogaty1, R J White, D R Phillips, J A Reiss.   

Abstract

The DNA-sequence specificity of daunomycin was investigated by DNase I footprinting and an E. coli RNA polymerase transcription-inhibition assay. The 5'-CA sequence was identified as being the highest affinity binding site, although other modest affinity (5'-GC, CG, CT, TC, AC) and poor affinity sites (5'-AA, AT, TA) were also observed. The preference of daunomycin for 5'-CA nucleotide sequence suggests that its biological activity may arise from association with the 5'-CA-containing sequences thought to be associated with genetic regulatory elements in eukaryotes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828115     DOI: 10.1016/0014-5793(88)80877-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  The interaction of Fe(III), adriamycin and daunomycin with nucleotides and DNA and their effects on cell growth of fibroblasts (NIH-3T3).

Authors:  I Di Liegro; A Cestelli; B F Matzanke; E Bill; A X Trautwein
Journal:  Biometals       Date:  1996-04       Impact factor: 2.949

2.  Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.

Authors:  Na Zhao; Qixin Leng; Martin C Woodle; A James Mixson
Journal:  Biochem Biophys Res Commun       Date:  2019-04-04       Impact factor: 3.575

3.  In vitro transcription analysis of the role of flanking sequence on the DNA sequence specificity of adriamycin.

Authors:  H Trist; D R Phillips
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

4.  Bis-daunomycin hydrazones: interactions with DNA.

Authors:  D R Phillips; R T Brownlee; J A Reiss; P A Scourides
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

5.  Mutation induced conformational changes in genomic DNA from cancerous K562 cells influence drug-DNA binding modes.

Authors:  Debjani Ghosh; Subrata Kumar Dey; Chabita Saha
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.